Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: Efficacy and safety - A preliminary report

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue SUPPL. 1, 1999, Pages

  Bick, Rodger L ^a,b,c   Rice, Jennifer ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Dallas Thromb Hemostasis Vasc M   (United States)

^c NONE   (United States)

Author keywords

Dalteparin; Long term heparin; Low molecular weight heparin; Outpatient heparin

Indexed keywords

DALTEPARIN; HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; FEMALE; HUMAN; LIVER TOXICITY; MALE; MONOCYTOSIS; NEPHROTOXICITY; OSTEOPOROSIS; OUTPATIENT CARE; PRIORITY JOURNAL; SKIN ALLERGY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VEIN THROMBOSIS;

EID: 0032755971     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/10760296990050s112     Document Type: Conference Paper

References (16)

1. Bick RL. Antithrombotic therapy. In: Bick, Bennett, Brynes, et. al. eds. Hematology: Clinical and laboratory practice. St. Louis: Mosby, 1993, chapter 102.
2. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975.
3. van den Belt AGM, Prins MH, Lensing AWA, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. (Cochrane Review) In: The Cochrane Library, Issue 2. Oxford: 1998.
4. Bick RL, Kaplan H. Syndromes causing hypercoagulability and thrombosis. Med Clin North Am 1998;82:409.
5. Bick RL. The antiphospholipid thrombosis syndromes: a common multidisciplinary medical problem. Clin Appl Thromb Hemost 1997;3:270.
6. Bick RL, Strauss JF, Rutherford CJ, et al. Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am 1996; 10:875.
7. Bick RL. Sticky platelet syndrome: a common cause of arterial and venous thrombosis. J Clin Appl Thromb Hemost 1998;4:77.
8. Walenga J, Bick RL. Heparin associated thrombocytopenia and other adverse effects of heparin therapy. Med Clin North Am 1998; 82:635.
9. Walenga J, Bick RL. Heparin associated thrombocytopenia and other adverse effects of heparin therapy. Cardiol Clin (Annual of Drug Therapy) 1998;2:123.
10. Bick RL. Therapy for venous thrombosis: guidelines for a competent and cost-effective approach. Clin Appl Throm Hemost 1999;5:2.
11. Wallentin L. for the FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347:561.
12. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 1997;96:61.
13. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447.
14. Muir JM, Andrew M, Hirsh J. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 1996; 88:1314
15. Samama MM, Bara L, Gouin-Thibault I. New data on the pharmacology of heparin and low molecular weight heparins. Drugs 1996;52(Suppl. 7):8.
16. Bircher AJ, Itin PH, Buchner SA. Skin lesions, hypereosinophilia and subcutaneous heparin. N Engl J Med 1994;343:861.